🇺🇸 FDA
Patent

US 11603412

Antibodies against CDCP1 for the treatment and detection of cancer

granted A61KA61K47/68031A61K47/6849

Quick answer

US patent 11603412 (Antibodies against CDCP1 for the treatment and detection of cancer) held by The Regents of the University of California expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K47/68031, A61K47/6849, A61P, A61P35/00